<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">HET</journal-id>
<journal-id journal-id-type="hwp">sphet</journal-id>
<journal-id journal-id-type="nlm-ta">Hum Exp Toxicol</journal-id>
<journal-title>Human &amp; Experimental Toxicology</journal-title>
<issn pub-type="ppub">0960-3271</issn>
<issn pub-type="epub">1477-0903</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0960327111417271</article-id>
<article-id pub-id-type="publisher-id">10.1177_0960327111417271</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The relationship among acute-phase responce proteins, cytokines, and hormones in various gastrointestinal cancer types patients with cachectic</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Kemik</surname>
<given-names>O</given-names>
</name>
<xref ref-type="aff" rid="aff1-0960327111417271">1</xref>
<xref ref-type="corresp" rid="corresp1-0960327111417271"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kemik</surname>
<given-names>AS</given-names>
</name>
<xref ref-type="aff" rid="aff2-0960327111417271">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Begenik</surname>
<given-names>H</given-names>
</name>
<xref ref-type="aff" rid="aff3-0960327111417271">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Erdur</surname>
<given-names>FM</given-names>
</name>
<xref ref-type="aff" rid="aff3-0960327111417271">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Emre</surname>
<given-names>H</given-names>
</name>
<xref ref-type="aff" rid="aff3-0960327111417271">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sumer</surname>
<given-names>A</given-names>
</name>
<xref ref-type="aff" rid="aff1-0960327111417271">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Purisa</surname>
<given-names>S</given-names>
</name>
<xref ref-type="aff" rid="aff4-0960327111417271">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tuzun</surname>
<given-names>S</given-names>
</name>
<xref ref-type="aff" rid="aff5-0960327111417271">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kotan</surname>
<given-names>C</given-names>
</name>
<xref ref-type="aff" rid="aff1-0960327111417271">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-0960327111417271"><label>1</label>Department of General Surgery, Yuzuncu Yı;l University Medical Faculty, Van, Turkey</aff>
<aff id="aff2-0960327111417271"><label>2</label>Department of Biochemistry, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey</aff>
<aff id="aff3-0960327111417271"><label>3</label>Department of Internal Medicine, Yuzuncu Yı;l University Medical Faculty, Van, Turkey</aff>
<aff id="aff4-0960327111417271"><label>4</label>Department of Biostatistics, Istanbul Medical Faculty, University of Istanbul, Istanbul, Turkey</aff>
<aff id="aff5-0960327111417271"><label>5</label>Department of General Surgery, Haseki Education and Research Hospital, Istanbul, Turkey</aff>
<author-notes>
<corresp id="corresp1-0960327111417271">Ozgur Kemik, Yüzüncü Yı;l Üniversitesi Tı;p Fakültesi Eğitim ve Araştı;rma Hastanesi, Genel Cerrahi Kliniği, Van, Turkey Email: <email>ozgurkemik@hotmail.com</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>2</month>
<year>2012</year>
</pub-date>
<volume>31</volume>
<issue>2</issue>
<fpage>117</fpage>
<lpage>125</lpage>
<permissions>
<copyright-statement>© SAGE Publications 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>
<bold>Background:</bold> Acute-phase response proteins (APRPs), cytokines, and hormones have been claimed to be an independent, important factor of cancers. We suggest that in gastrointestinal system cancers, changes in APRP, cytokines, and hormones are associated.<bold>Methods:</bold> C-reactive protein (CRP), albumin, interleukin 1α (IL-1α), IL-1β, IL-6, IL-8, IL-10, tumor necrosis factor α (TNF-α), midkine, vascular endothelial growth factor-A(VEGF-A), VEGF-C, VEGF receptor 1 (VEGFR1), leptin, adiponectin, and ghrelin serum levels are studied in 148 gastrointestinal system cancer types and 40 healthy controls.<bold>Results:</bold> We found statistically significant differences and correlations between groups. We found significantly higher serum CRP, IL-1α, IL-1β, IL-6, IL-8, IL-10, TNF-α, VEGF-A, VEGF-C, VEGFR1, and leptin concentrations in patients with esophageal, gastric, pancreas, colon, and rectum cancers than controls (<italic>p</italic> &lt; 0.001, <italic>p</italic> &lt; 0.0001). But, we found lower levels of the serum albumin, midkine, adiponectin, and ghrelin in patients with esophageal, gastric, pancreas, colon, and rectum cancers compared to control subjects (<italic>p</italic> &lt; 0.05, <italic>p</italic> &lt; 0.001).<bold>Conclusions:</bold> Cachexia in gastrointestinal system cancer types is associated with changes in APRP, cytokines, and hormone concentrations. This may be reflected between the outcomes in malignancies and the biomarkers.</p>
</abstract>
<kwd-group>
<kwd>acute-phase response protein</kwd>
<kwd>cytokines</kwd>
<kwd>hormones</kwd>
<kwd>cachexia</kwd>
<kwd>gastrointestinal cancer types</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0960327111417271">
<title>Introduction</title>
<p>Cachexia is often seen in end-stage cancer,<sup><xref ref-type="bibr" rid="bibr1-0960327111417271">1</xref></sup> it accounts for up to 40–50% of cancer-associated deaths in gastrointestinal tract malignancies.<sup><xref ref-type="bibr" rid="bibr2-0960327111417271">2</xref></sup> Cachexia is a convoluted metabolic disorder, including loss of adipose tissue due to lipolysis, loss of skeletal muscle mass, increase in reposing energy expenditure, anorexia, and reduction in oral food intake.<sup><xref ref-type="bibr" rid="bibr3-0960327111417271">3</xref>,<xref ref-type="bibr" rid="bibr4-0960327111417271">4</xref></sup>
</p>
<p>Even though consistent studies have been conducted thus far in this field, the multifactorial pathological mechanism of cancer-associated cachexia has not been faithfully expounded, therefore conformable treatment modalities are not adequate.<sup><xref ref-type="bibr" rid="bibr5-0960327111417271">5</xref></sup>
</p>
<p>It is not widely known that cytokine upregulation espouse results in involuntary weight loss, an influence of cancer-associated cachexia.<sup><xref ref-type="bibr" rid="bibr6-0960327111417271">6</xref>,<xref ref-type="bibr" rid="bibr7-0960327111417271">7</xref></sup> Though the catabolism preeminently acts as intermediary by the effects of some cytokines, such as tumor necrosis factor α (TNF-α), interleukin 1β (IL-1β), interleukin 6 (IL-6), and interleukin 10 (IL-10),<sup><xref ref-type="bibr" rid="bibr4-0960327111417271">4</xref>,<xref ref-type="bibr" rid="bibr8-0960327111417271">8</xref></sup> the mechanisms associated with cancer-cachexia are still not shown.<sup><xref ref-type="bibr" rid="bibr9-0960327111417271">9</xref></sup>
</p>
<p>Recent studies reporting cachexia in various gastrointestinal system cancers reported that some proinflammatory cytokines, such as IL-8 and, cytokines such as vascular endothelial growth factor-A (VEGF-A) and its receptor (VEGFR-1), and midkine might be involved in the process of cachexia.<sup><xref ref-type="bibr" rid="bibr10-0960327111417271">10</xref></sup> In addition, the proteins, such as cytokines and some hormones that import central mechanisms, are geared towards the regulation of the energy homeostasis.<sup><xref ref-type="bibr" rid="bibr11-0960327111417271">11</xref></sup> These hormones are the adiponectin, ghrelin, and leptin.<sup><xref ref-type="bibr" rid="bibr11-0960327111417271">11</xref>,<xref ref-type="bibr" rid="bibr12-0960327111417271">12</xref></sup>
</p>
<p>Adiponectin is a member of a group of proteins secreted from adipocytes.<sup><xref ref-type="bibr" rid="bibr13-0960327111417271">13</xref></sup> There is significant inverse correlation between serum adiponectin levels and body weight. Thus, reduction in adiponectin levels is detected in obesity<sup><xref ref-type="bibr" rid="bibr14-0960327111417271">14</xref>,<xref ref-type="bibr" rid="bibr15-0960327111417271">15</xref></sup> but high levels are found in anorexia nervosa<sup><xref ref-type="bibr" rid="bibr16-0960327111417271">16</xref></sup> and at the time of weight loss.<sup><xref ref-type="bibr" rid="bibr17-0960327111417271">17</xref></sup>
</p>
<p>There is significant association between decreased adiponectin levels and increased risk of breast, endometrial, and gastric cancers.<sup><xref ref-type="bibr" rid="bibr18-0960327111417271">18</xref><xref ref-type="bibr" rid="bibr19-0960327111417271"/>–<xref ref-type="bibr" rid="bibr20-0960327111417271">20</xref></sup> The mechanisms responsible for the regulation of adiponectin levels have not been fully acknowledged. Eventually, recent data suggest adiponectin was downregulated by TNF-α as well as by insulin.<sup><xref ref-type="bibr" rid="bibr21-0960327111417271">21</xref></sup>
</p>
<p>The hormone ghrelin is a 28 amino acid peptide, its third serine residue is esterified by n-octanoic acid.<sup><xref ref-type="bibr" rid="bibr22-0960327111417271">22</xref></sup> The stomach is the master source of ghrelin.</p>
<p>The peptide increases the release growth hormone (GH) from the pituitary and hypothalamus.<sup><xref ref-type="bibr" rid="bibr23-0960327111417271">23</xref></sup>
</p>
<p>Ghrelin is produced in the hypothalamic arcuate nucleus, where it stimulates the secretion of growth hormone from the anterior pituitary gland. Ghrelin also enhances the motility of gastrointestinal tract, as does motilin. Ghrelin also appears to promote gastrointestinal malignancy.<sup><xref ref-type="bibr" rid="bibr24-0960327111417271">24</xref></sup>
</p>
<p>High ghrelin levels are related to multifarious cachectic juncture, such as anorexia nervosa and forceful heart failure.<sup><xref ref-type="bibr" rid="bibr25-0960327111417271">25</xref></sup> Enhanced ghrelin levels were recently made evident in lung cancer-conduced cachexia,<sup><xref ref-type="bibr" rid="bibr26-0960327111417271">26</xref></sup> and in male patients with primarily liable lung and prostate cancer.<sup><xref ref-type="bibr" rid="bibr27-0960327111417271">27</xref></sup>
</p>
<p>Leptin is an member of the adipocytokine family. It is manufactured by the differentiation of adipocytes and affects the central nervous system to suppress food intake and stimulates energy expenditure.<sup><xref ref-type="bibr" rid="bibr12-0960327111417271">12</xref></sup> Higher leptin serum levels are found in anorexia nervosa patients.<sup><xref ref-type="bibr" rid="bibr28-0960327111417271">28</xref></sup>
</p>
<p>Association between acute-phase response proteins (APRPs) and weight loss in human cancer associated with cachexia has been showed exclusively in pancreatic carcinoma and in melanoma.<sup><xref ref-type="bibr" rid="bibr29-0960327111417271">29</xref><xref ref-type="bibr" rid="bibr30-0960327111417271"/>–<xref ref-type="bibr" rid="bibr31-0960327111417271">31</xref></sup>
</p>
<p>Midkine is a heparin-binding growth factor found as the product of a retinoic acid-responsive gene.<sup><xref ref-type="bibr" rid="bibr32-0960327111417271">32</xref></sup> Since midkine is a secreted protein, serum midkine levels are expected to increase when tumor tissues largely express midkine.</p>
<p>The aim of our study was to show the associations between cachexia due to weight loss and cachexia due to APRPs, albumin, C-reactive protein (CRP) and cytokines and its receptor (IL-1α, IL-1β, IL-6, IL-10, TNF-α, IL-8, VEGF-A, VEGF-C, and VEGFR1), midkine, and hormones (adiponectin, leptin, and ghrelin) in patients with various gastrointestinal system cancers.</p>
</sec>
<sec id="section2-0960327111417271">
<title>Materials and methods</title>
<sec id="section3-0960327111417271">
<title>Patients</title>
<p>A total of 148 patients with gastrointestinal cancer (32 esophageal cancer type, 31 gastric cancer, 32 colon cancer, 18 pancreatic cancers, 35 rectum cancer) were enrolled in our study. Exclusion criteria included previous treatment by chemotherapy, radiotherapy, or a major operation history 6 months before the recovery; brain metastasis; second malignancy; acute or chronic infections; dysphagia; other primary cachectic states (i.e. congestive pulmonary disease and cirrhosis); elevated bilirubin or liver enzymes (&gt;2 of the upper normal reference value); renal failure (creatinine &gt;2 mg/dl); history of eating disorders; or gastrectomy.</p>
<p>Demographic clinical and anthropometric data were collected during the recovery period. All pathology reports were reviewed, and data on tumor histology were recorded. Stage was defined according to the 1997 American Joint Committee on Cancer Staging System.<sup><xref ref-type="bibr" rid="bibr33-0960327111417271">33</xref></sup>
</p>
<p>We used sera from blood donors considered healthy on the basis of routine blood tests, to obtain the reference values in this study. The reference group consisted of 40 individuals, 18 females and 22 males, with a median age of 41 years (range 37–71 years). Healthy samples obtained from 40 normal healthy volunteers were used as controls. The absence of disease such as infection and asymptomatic early adenocarcinoma and adenoma was assessed by clinical history, physical examination, routine laboratory tests, including liver and renal function tests, and colonoscopy.</p>
<p>Body mass index (BMI) was calculated as weight (kg) divided by height (m<sup>2</sup>), and cachexia was defined as ≥5% reduction in BMI at the time of recovery. The study protocol was approved by the medical Ethics Committee of Yuzuncu Yı;l University, Medical Faculty Hospital, Van, and was in accordance with the ethical standards formulated in the Helsinki Declaration of 1975. Informed consent was obtained from all subjects.</p>
</sec>
<sec id="section4-0960327111417271">
<title>Biochemical methods</title>
<p>The concentrations of all parameters in the examined samples were measured in sera obtained from blood drawn in the fasting state, clotted (15 min, room temperature) and centrifuged (15 min, 1000 <italic>g</italic>). The serum samples were then immediately frozen at −80°C until further analysis (except albumin, CRP, and midkine). The albumin concentrations were measured colorimetrically as a complex of albumin with bromocresol blue dye under acidic conditions. High-sensitive CRP was determined by the immunonephelometry (Behring Nephelometer II). Serum midkine concentrations were assayed with indirect enzyme-linked immunosorbent assay (ELISA; R&amp;D Systems, USA) and anti-human midkine polyclonal antibodies were used. The serum concentrations of IL-1α, IL-1β, IL-6, IL-8, and TNF-α were assayed using a validated commercial ELISA (Quantikine R&amp;D Systems, Minneapolis, MN, USA). The IL-10 levels were measured using the Endogen Inc. assay (Cambridge). The concentrations of VEGF-A, VEGF-C, and VEGFR1 were measured in duplicate with a commercially available quantitative sandwich enzyme immunoassay kit (R&amp;D Systems, USA). Adiponectin, ghrelin, and leptin concentrations were determined using radioimmunoassay kits (Linco Research, St. Charles, MO, USA).</p>
</sec>
<sec id="section5-0960327111417271">
<title>Statistical analysis</title>
<p>Data are presented as mean ± SD. Comparisons were performed with the nonparametric Mann-Whitney <italic>U</italic> test for continuous variables and with the χ<sup>2</sup> tests for categorical data. The comparison of all cancer types and control samples was done using one-way analysis of variance (ANOVA) test. Differences between groups were determined using the log-rank test. Two-sided <italic>p</italic> values &lt;0.05 were considered statistically significant.</p>
</sec>
</sec>
<sec id="section6-0960327111417271">
<title>Results</title>
<p>There were no differences in terms of age between the patients and the control groups (<italic>p</italic> &gt; 0.05). All parameters and all groups were examined in terms of age and there were no significant differences (<italic>p</italic> &gt; 0.05). There were no gender differences in plasma leptin levels (<italic>p</italic> &gt; 0.05) in all patients.</p>
<p>We found significantly higher levels of the serum CRP, IL-1α, IL-1β, IL-6, IL-8, IL-10, TNF-α, VEGF-A, VEGF-C, VEGFR1, and leptin concentrations in patients with esophageal, gastric, pancreas, colon, and rectum cancer than the controls (<italic>p</italic> &lt; 0.001, <italic>p</italic> &lt; 0.0001). Otherwise, we found lower levels of the serum albumin, midkine, adiponectin, and ghrelin in patients with esophageal, gastric, pancreas, colon, and rectum compared to the controls (<italic>p</italic> &lt; 0.05, <italic>p</italic> &lt; 0.01, <italic>p</italic> &lt; 0.001; <xref ref-type="table" rid="table1-0960327111417271">Tables 1</xref>–<xref ref-type="table" rid="table5-0960327111417271">5</xref>).</p>
<table-wrap id="table1-0960327111417271" position="float">
<label>Table 1.</label>
<caption>
<p>Concentrations of all parameters in patients with esophageal cancer and in controls</p>
</caption>
<graphic alternate-form-of="table1-0960327111417271" xlink:href="10.1177_0960327111417271-table1.tif"/>
<table>
<thead>
<tr>
<th>Parameters</th>
<th>Patients</th>
<th>Controls</th>
<th>
<italic>p</italic>
</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (y)</td>
<td>49.1 ± 10.2</td>
<td>40.4 ± 11.3</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Gender (F/M)</td>
<td>17/15</td>
<td>22/18</td>
<td>
</td>
</tr>
<tr>
<td>BMI (kg/m<sup>2</sup>)</td>
<td>15.0 ± 1.3</td>
<td>21.5 ± 2.0</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>CRP (ng/ml)</td>
<td>8.7 ± 3.1</td>
<td>3.5 ± 2.1</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Albumin (mg/dl)</td>
<td>2.1 ± 1.4</td>
<td>4.4 ± 1.1</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Midkine (ng/ml)</td>
<td>0.28 ± 0.02</td>
<td>0.36 ± 0.1</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>VEGF-A (pg/ml)</td>
<td>948.1 ± 205.6</td>
<td>309.4 ± 135.8</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>VEGF-C (pg/ml)</td>
<td>4824.9 ± 854.9</td>
<td>1736.9 ± 685.8</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>VEGFR1 (pg/ml)</td>
<td>758.9 ± 142.7</td>
<td>97.5 ± 21.4</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>IL-1α (pg/ml)</td>
<td>694.5 ± 196.0</td>
<td>209.6 ± 102.3</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>IL-1β (pg/ml)</td>
<td>689.8 ± 286.5</td>
<td>276.9 ± 132.2</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>IL-6 (pg/ml)</td>
<td>126.7 ± 54.2</td>
<td>34.9 ± 29.7</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>IL-8 (pg/ml)</td>
<td>70.1 ± 24.1</td>
<td>29.5 ± 19.6</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>IL-10 (pg/ml)</td>
<td>4.5 ± 1.2</td>
<td>2.3 ± 1.1</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>TNF-α (pg/ml)</td>
<td>19 ± 10</td>
<td>10 ± 7</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Leptin (ng/ml)</td>
<td>45.2 ± 12.5</td>
<td>23.8 ± 11.4</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Adiponectin (μg/ml)</td>
<td>4.1 ± 2.0</td>
<td>6.5 ± 1.4</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Ghrelin (pmol/l)</td>
<td>163.9 ± 72.8</td>
<td>300.9 ± 57.3</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0960327111417271">
<p>BMI: body mass index, CRP: C-reactive protein, IL: interleukin, TNF: tumor necrosis factor, VEGF: vascular endothelial growth factor, VEGFR1: VEGF receptor 1.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table2-0960327111417271" position="float">
<label>Table 2.</label>
<caption>
<p>Concentrations of all parameters in patients with gastric cancer and in controls</p>
</caption>
<graphic alternate-form-of="table2-0960327111417271" xlink:href="10.1177_0960327111417271-table2.tif"/>
<table>
<thead>
<tr>
<th>Parameters</th>
<th>Patients</th>
<th>Controls</th>
<th>
<italic>p</italic>
</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (y)</td>
<td>46.8 ± 11.9</td>
<td>40.4 ± 11.3</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Gender (F/M)</td>
<td>14/17</td>
<td>22/18</td>
<td>
</td>
</tr>
<tr>
<td>BMI (kg/m<sup>2</sup>)</td>
<td>16.2 ± 1.5</td>
<td>21.5 ± 2.0</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>CRP (ng/ml)</td>
<td>9.0 ± 4.8</td>
<td>3.5 ± 2.1</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Albumin (mg/dl)</td>
<td>2.6 ± 1.4</td>
<td>4.4 ± 1.1</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Midkine (ng/ml)</td>
<td>0.24 ± 0.029</td>
<td>0.36 ± 0.1</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>VEGF-A (pg/ml)</td>
<td>648.3 ± 213.9</td>
<td>309.4 ± 135.8</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>VEGF-C (pg/ml)</td>
<td>3559.4 ± 903.2</td>
<td>1736.9 ± 685.8</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>VEGFR1 (pg/ml)</td>
<td>475.9 ± 103.5</td>
<td>97.5 ± 21.4</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>IL-1α (pg/ml)</td>
<td>799.8 ± 231.8</td>
<td>209.6 ± 102.3</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>IL-1β (pg/ml)</td>
<td>612.4 ± 289.4</td>
<td>276.9 ± 132.2</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>IL-6 (pg/ml)</td>
<td>114.9 ± 31.5</td>
<td>34.9 ± 29.7</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>IL-8 (pg/ml)</td>
<td>83.1 ± 19.6</td>
<td>29.5 ± 19.6</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>IL-10 (pg/ml)</td>
<td>6.3 ± 1.7</td>
<td>2.3 ± 1.1</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>TNF-α (pg/ml)</td>
<td>29 ± 17</td>
<td>10 ± 7</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Leptin (ng/ml)</td>
<td>40.8 ± 13.5</td>
<td>23.8 ± 11.4</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Adiponectin (μg/ml)</td>
<td>5.1 ± 1.8</td>
<td>6.5 ± 1.4</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Ghrelin (pmol/l)</td>
<td>197.2 ± 73.8</td>
<td>300.9 ± 57.3</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-0960327111417271">
<p>BMI: body mass index, CRP: C-reactive protein, IL: interleukin, TNF: tumor necrosis factor, VEGF: vascular endothelial growth factor.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table3-0960327111417271" position="float">
<label>Table 3.</label>
<caption>
<p>Concentrations of all parameters in patients with pancreas cancer and in controls</p>
</caption>
<graphic alternate-form-of="table3-0960327111417271" xlink:href="10.1177_0960327111417271-table3.tif"/>
<table>
<thead>
<tr>
<th>Parameters</th>
<th>Patients</th>
<th>Controls</th>
<th>
<italic>p</italic>
</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (y)</td>
<td>49.1 ± 12.4</td>
<td>40.4 ± 11.3</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Gender (F/M)</td>
<td>10/8</td>
<td>22/18</td>
<td>
</td>
</tr>
<tr>
<td>BMI (kg/m<sup>2</sup>)</td>
<td>16.6 ± 1.9</td>
<td>21.5 ± 2.0</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>CRP (ng/ml)</td>
<td>9.9 ± 3.5</td>
<td>3.5 ± 2.1</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Albumin (mg/dl)</td>
<td>2.9 ± 1.1</td>
<td>4.4 ± 1.1</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Midkine (ng/ml)</td>
<td>0.23 ± 0.02</td>
<td>0.36 ± 0.1</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>VEGF-A (pg/ml)</td>
<td>960.4 ± 136.2</td>
<td>309.4 ± 135.8</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>VEGF-C (pg/ml)</td>
<td>4234.6 ± 829.8</td>
<td>1736.9 ± 685.8</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>VEGFR1 (pg/ml)</td>
<td>420.2 ± 98.5</td>
<td>97.5 ± 21.4</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>IL-1α (pg/ml)</td>
<td>696.0 ± 264.2</td>
<td>209.6 ± 102.3</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>IL-1β (pg/ml)</td>
<td>657.2 ± 283.1</td>
<td>276.9 ± 132.2</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>IL-6 (pg/ml)</td>
<td>238.7 ± 37.4</td>
<td>34.9 ± 29.7</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>IL-8 (pg/ml)</td>
<td>83.9 ± 13.5</td>
<td>29.5 ± 19.6</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>IL-10 (pg/ml)</td>
<td>6.4 ± 1.5</td>
<td>2.3 ± 1.1</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>TNF-α (pg/ml)</td>
<td>30 ± 9</td>
<td>10 ± 7</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Leptin (ng/ml)</td>
<td>41.7 ± 10.3</td>
<td>23.8 ± 11.4</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Adiponectin (μg/ml)</td>
<td>2.9 ± 1.0</td>
<td>6.5 ± 1.4</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Ghrelin (pmol/l)</td>
<td>184.6 ± 73.1</td>
<td>300.9 ± 57.3</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-0960327111417271">
<p>BMI: body mass index, CRP: C-reactive protein, IL: interleukin, TNF: tumor necrosis factor, VEGF: vascular endothelial growth factor, VEGFR1: VEGF receptor 1.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table4-0960327111417271" position="float">
<label>Table 4.</label>
<caption>
<p>Concentrations of all parameters in patients with colon cancer and in controls</p>
</caption>
<graphic alternate-form-of="table4-0960327111417271" xlink:href="10.1177_0960327111417271-table4.tif"/>
<table>
<thead>
<tr>
<th>Parameters</th>
<th>Patients</th>
<th>Controls</th>
<th>
<italic>p</italic>
</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (y)</td>
<td>49.5 ± 12.3</td>
<td>40.4 ± 11.3</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Gender (F/M)</td>
<td>18/16</td>
<td>22/18</td>
<td>
</td>
</tr>
<tr>
<td>BMI (kg/m<sup>2</sup>)</td>
<td>15.9 ± 1.9</td>
<td>21.5 ± 2.0</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>CRP (ng/ml)</td>
<td>9.1 ± 2.9</td>
<td>3.5 ± 2.1</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Albumin (mg/dl)</td>
<td>4.7 ± 1.8</td>
<td>4.4 ± 1.1</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Midkine (ng/ml)</td>
<td>0.63 ± 0.051</td>
<td>0.36 ± 0.1</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>VEGF-A (pg/ml)</td>
<td>789.7 ± 200.8</td>
<td>309.4 ± 135.8</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>VEGF-C (pg/ml)</td>
<td>4135.2 ± 910.6</td>
<td>1736.9 ± 685.8</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>VEGFR1 (pg/ml)</td>
<td>886.9 ± 274.0</td>
<td>97.5 ±21.4</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>IL-1α (pg/ml)</td>
<td>850.2 ± 143.1</td>
<td>209.6 ± 102.3</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>IL-1β (pg/ml)</td>
<td>646.0 ± 240.7</td>
<td>276.9 ± 132.2</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>IL-6 (pg/ml)</td>
<td>131.5 ± 30.6</td>
<td>34.9 ± 29.7</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>IL-8 (pg/ml)</td>
<td>86.4 ± 20.3</td>
<td>29.5 ± 19.6</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>IL-10 (pg/ml)</td>
<td>4.9 ± 0.9</td>
<td>2.3 ± 1.1</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>TNF-α (pg/ml)</td>
<td>43 ± 17</td>
<td>10 ± 7</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Leptin (ng/ml)</td>
<td>58.9 ± 11.5</td>
<td>23.8 ± 11.4</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Adiponectin (μg/ml)</td>
<td>4.8 ± 1.0</td>
<td>6.5 ± 1.4</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Ghrelin (pmol/l)</td>
<td>139.4 ± 51.0</td>
<td>300.9 ± 57.3</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-0960327111417271">
<p>BMI: body mass index, CRP: C-reactive protein, IL: interleukin, TNF: tumor necrosis factor, VEGF: vascular endothelial growth factor, VEGFR1: VEGF receptor 1.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table5-0960327111417271" position="float">
<label>Table 5.</label>
<caption>
<p>Concentrations of all parameters in patients with rectum cancer and in controls</p>
</caption>
<graphic alternate-form-of="table5-0960327111417271" xlink:href="10.1177_0960327111417271-table5.tif"/>
<table>
<thead>
<tr>
<th>Parameters</th>
<th>Patients</th>
<th>Controls</th>
<th>
<italic>p</italic>
</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (y)</td>
<td>44.8 ± 11.4</td>
<td>40.4 ± 11.3</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Gender (F/M)</td>
<td>19/16</td>
<td>22/18</td>
<td>
</td>
</tr>
<tr>
<td>BMI (kg/m<sup>2</sup>)</td>
<td>16.2 ± 1.2</td>
<td>21.5 ± 2.0</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>CRP (ng/ml)</td>
<td>9.1 ± 3.2</td>
<td>3.5 ± 2.1</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Albumin (mg/dl)</td>
<td>2.3 ± 0.9</td>
<td>4.4 ± 1.1</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Midkine (ng/ml)</td>
<td>0.26 ± 0.037</td>
<td>0.36 ± 0.1</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>VEGF-A (pg/ml)</td>
<td>775.9 ± 126.2</td>
<td>309.4 ± 135.8</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>VEGF-C (pg/ml)</td>
<td>3986.4 ± 563.2</td>
<td>1736.9 ± 685.8</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>VEGFR1 (pg/ml)</td>
<td>583.9 ± 195.9</td>
<td>97.5 ± 21.4</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>IL-1α (pg/ml)</td>
<td>910.3 ± 316.0</td>
<td>209.6 ± 102.3</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>IL-1β (pg/ml)</td>
<td>780.7 ± 288.4</td>
<td>276.9 ± 132.2</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>IL-6 (pg/ml)</td>
<td>227.4 ± 68.1</td>
<td>34.9 ± 29.7</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>IL-8 (pg/ml)</td>
<td>73.7 ± 20.9</td>
<td>29.5 ± 19.6</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>IL-10 (pg/ml)</td>
<td>4.9 ± 1.3</td>
<td>2.3 ± 1.1</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>TNF-α (pg/ml)</td>
<td>29 ± 17</td>
<td>10 ± 7</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Leptin (ng/ml)</td>
<td>50.4 ± 13.7</td>
<td>23.8 ± 11.4</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Adiponectin (μg/ml)</td>
<td>4.7 ± 2.0</td>
<td>6.5 ± 1.4</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Ghrelin (pmol/l)</td>
<td>192.7 ± 58.3</td>
<td>300.9 ± 57.3</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn5-0960327111417271">
<p>BMI: body mass index, CRP: C-reactive protein, IL: interleukin, TNF: tumor necrosis factor, VEGF: vascular endothelial growth factor, VEGFR1: VEGF receptor 1.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>There were no gender differences in plasma leptin, adiponectin, ghrelin levels, and BMI index (<italic>p</italic> &gt; 0.05) in all patients (<xref ref-type="table" rid="table6-0960327111417271">Table 6</xref>).</p>
<table-wrap id="table6-0960327111417271" position="float">
<label>Table 6.</label>
<caption>
<p>Hormone levels in female and male patients</p>
</caption>
<graphic alternate-form-of="table6-0960327111417271" xlink:href="10.1177_0960327111417271-table6.tif"/>
<table>
<thead>
<tr>
<th>
</th>
<th>Female</th>
<th>Male</th>
<th>
<italic>p</italic>
</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="4">Esophageal cancer</td>
</tr>
<tr>
<td> BMI (kg/m<sup>2</sup>)</td>
<td>14.9 ± 0.5</td>
<td>15.1 ± 0.3</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td> Leptin (ng/ml)</td>
<td>41.3 ± 11.9</td>
<td>44.8 ± 14.2</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td> Adiponectin (μg/ml)</td>
<td>3.2 ± 0.8</td>
<td>2.9 ± 1.3</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td> Ghrelin (pmol/l)</td>
<td>162.7 ± 75.9</td>
<td>170.3 ± 60.1</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td colspan="4">Gastric cancer</td>
</tr>
<tr>
<td> BMI (kg/m<sup>2</sup>)</td>
<td>15.3 ± 1.0</td>
<td>15.8 ± 1.1</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td> Leptin (ng/ml)</td>
<td>38.1 ± 10.3</td>
<td>41.2 ± 11.9</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td> Adiponectin (μg/ml)</td>
<td>4.9 ± 2.1</td>
<td>4.5 ± 2.0</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td> Ghrelin (pmol/l)</td>
<td>199.1 ± 45.2</td>
<td>191.5 ± 68.6</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td colspan="4">Pancreatic cancer</td>
</tr>
<tr>
<td> BMI (kg/m<sup>2</sup>)</td>
<td>15.9 ± 1.5</td>
<td>16.3 ± 1.0</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Leptin (ng/ml)</td>
<td>43.2 ± 13.1</td>
<td>41.9 ± 10.4</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td> Adiponectin (μg/ml)</td>
<td>3.1 ± 1.0</td>
<td>3.0 ± 0.9</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td> Ghrelin (pmol/l)</td>
<td>180.1 ± 59.8</td>
<td>182.9 ± 70.1</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td colspan="4">Colon cancer</td>
</tr>
<tr>
<td> BMI (kg/m<sup>2</sup>)</td>
<td>15.7 ± 1.3</td>
<td>16.1 ± 1.0</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td> Leptin (ng/ml)</td>
<td>42.3 ± 11.9</td>
<td>47.4 ± 9.3</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Adiponectin (μg/ml)</td>
<td>4.1 ± 1.5</td>
<td>4.0 ± 1.7</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td> Ghrelin (pmol/l)</td>
<td>140.6 ± 41.7</td>
<td>146.8 ± 40.9</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td colspan="4">Rectum cancer</td>
</tr>
<tr>
<td> BMI (kg/m<sup>2</sup>)</td>
<td>15.2 ± 0.9</td>
<td>15.9 ± 0.8</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td> Leptin (ng/ml)</td>
<td>49.9 ± 10.3</td>
<td>49.8 ± 11.9</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td> Adiponectin (μg/ml)</td>
<td>4.2 ± 1.6</td>
<td>4.9 ± 1.1</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td> Ghrelin (pmol/l)</td>
<td>197.1 ± 60.3</td>
<td>190.2 ± 71.0</td>
<td>&gt;0.05</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn6-0960327111417271">
<p>BMI: body mass index.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>We found the correlation between BMI loss and adiponectin levels in all patients (<italic>p</italic> &lt; 0.01, <italic>r</italic> = 0.71). Also, we found a positive correlation between midkine and albumin; similarly between both BMI loss and plasma leptin levels; BMI loss and midkine; BMI loss and albumin; and IL-6 and TNF-α in all patients (respectively, <italic>p</italic> &lt; 0.001, <italic>r</italic> = 0.69, <italic>r</italic> = 0.71, <italic>r</italic> = 0.59, <italic>r</italic> = 0.63, <italic>r</italic> = 0.75).</p>
<p>There was significant positive correlation between BMI loss and VEGF-A and VEGFR1 as well as VEGF-A and IL-1 (respectively, <italic>p</italic> &lt; 0.001, <italic>r</italic> = 0.78, <italic>r</italic> = 0.71).</p>
<p>Correlation between VEGF-A and IL-6 was similarly statistically significant (<italic>p</italic> &lt; 0.001, <italic>r</italic> = 0.74).</p>
</sec>
<sec id="section7-0960327111417271">
<title>Discussion</title>
<p>In our study, we determined the associations between acute-phase response and proinflammatory cytokines, cytokine, hormones and cancer-related cachexia in patients with various gastrointestinal system cancer types.</p>
<p>Systemic inflammation is a nonspecific procedure of many cancer types. Association between acute-phase-related proteins and accelerated weight loss has been characterized only in a few cancer types including pancreatic and lung cancers and in melanoma.<sup><xref ref-type="bibr" rid="bibr31-0960327111417271">31</xref></sup>
</p>
<p>Decreased albumin concentrations are associated with cachexia and gastrointestinal system cancers. Hypoalbuminemia has newly been showed to be a predictive factor of helpless responsiveness.<sup><xref ref-type="bibr" rid="bibr34-0960327111417271">34</xref>,<xref ref-type="bibr" rid="bibr35-0960327111417271">35</xref></sup> Our results showed that a weight-loss-dependent association with cachexia may assist the association of hypoalbuminemia with cachexia and all types of gastrointestinal system cancers. The decrease in transferring concentrations seems to be specially weight loss dependent. The ongoing systemic inflammatory response described in terms of CRP concentrations has newly carried some interest as an easy-to measure and well-standardized outcome predictor.<sup><xref ref-type="bibr" rid="bibr36-0960327111417271">36</xref>,<xref ref-type="bibr" rid="bibr37-0960327111417271">37</xref></sup>
</p>
<p>Similar to hardy weight loss,<sup><xref ref-type="bibr" rid="bibr10-0960327111417271">10</xref></sup> an elevation in CRP concentration has been related to increased importance of primary tumor and has been associated with deficient survival.<sup><xref ref-type="bibr" rid="bibr36-0960327111417271">36</xref>,<xref ref-type="bibr" rid="bibr37-0960327111417271">37</xref></sup> Our results may support the association of CRP concentrations and all cancer type-related cachexia.</p>
<p>The association of CRP with the proangiogenic environment may contribute to adverse effects together with CRP elevation.<sup><xref ref-type="bibr" rid="bibr38-0960327111417271">38</xref></sup>
</p>
<p>Our results describe a positive correlation between CRP, IL-8 and midkine, which have proangiogenic properties in all cancer types .<sup><xref ref-type="bibr" rid="bibr39-0960327111417271">39</xref></sup> Similarly CRP and VEGF correlation has been determined and these results may further support this hypothesis. It is also of interest that similar to CRP,<sup><xref ref-type="bibr" rid="bibr36-0960327111417271">36</xref>,<xref ref-type="bibr" rid="bibr37-0960327111417271">37</xref></sup> circulating midkine<sup><xref ref-type="bibr" rid="bibr10-0960327111417271">10</xref></sup> and IL-8<sup><xref ref-type="bibr" rid="bibr40-0960327111417271">40</xref></sup> have been found to reflect lymph node involvement in esophageal squamous cell carcinoma. The concentrations of IL-6 and midkine are independently associated with patients weight status, among IL-1, IL-8 and VEGF in cachectic cancer patients. TNF-α, IL-1, and IL-6 are the key cytokines involved in cancer-related cachexia. However, apart from IL-6, alterations in their systemic levels are seldom determined.<sup><xref ref-type="bibr" rid="bibr31-0960327111417271">31</xref></sup> As experimental cytokine-directed anti-cachectic therapies yielded moderate results,<sup><xref ref-type="bibr" rid="bibr31-0960327111417271">31</xref></sup> there is a need for finding other mediators of cancer cachexia.<sup><xref ref-type="bibr" rid="bibr5-0960327111417271">5</xref>,<xref ref-type="bibr" rid="bibr31-0960327111417271">31</xref></sup>
</p>
<p>We found midkine and VEGF to be the independent predictors of weight loss in patients with gastrointestinal system cancer. Our results supply evidence for an association of midkine and VEGF with systemic inflammation and malnutrition, supporting a probably involvement of these cytokines in the pathogenesis of cachexia. However, only the concentrations of VEGF and leptin, but not midkine, are associated with weight loss in the examined cohort of cancer patients. Midkine was related to inflammation and was correlated with albumin concentration, while the associations were not affected by cachexia. These together may further indicate VEGF as a procachectic cytokine, corroborating the findings of other authors, showing VEGF associations with standard procachectic cytokines. IL-1 and IL-6 have been propagated in the regulation of VEGF expression,<sup><xref ref-type="bibr" rid="bibr41-0960327111417271">41</xref></sup> while anti-TNF-α treatment (infliximab) has been described to decrease serum VEGF concentrations.<sup><xref ref-type="bibr" rid="bibr42-0960327111417271">42</xref></sup>
</p>
<p>We found that VEGF correlated with IL-1 and IL-6 merely in cachectic gastrointestinal cancer patients. Although the involvement of midkine in inflammation is well documented,<sup><xref ref-type="bibr" rid="bibr43-0960327111417271">43</xref></sup> only a weak correlation between midkine and CRP in cancer patients has been reported.<sup><xref ref-type="bibr" rid="bibr44-0960327111417271">44</xref></sup>
</p>
<p>Adiponectin levels are reported to be inversely correlated with body weight. Thus, voluntary weight loss, as well as anorexia nervosa, is associated with increased adiponectin levels.<sup>14,17,45</sup> However, in our study, we found no correlation between BMI loss and adiponectin levels. Adiponectin levels are regulated essentially by changes in the adipose tissue.<sup><xref ref-type="bibr" rid="bibr45-0960327111417271">45</xref></sup> The lack of association between adiponectin levels and weight loss may entirely reflect the preservation of adipose tissue. Recent studies have shown that the inhibition of adiponectin secretion from adipocytes by various cytokines, including TNF-α.<sup><xref ref-type="bibr" rid="bibr21-0960327111417271">21</xref>,<xref ref-type="bibr" rid="bibr46-0960327111417271">46</xref></sup> The lack of elevation of adiponectin levels after cancer cachexia may reflect altered regulation of adiponectin in this condition. Interestingly, lower adiponectin levels were also found in a cohort of cachectic patients with advanced stage of lung cancer compared with healthy volunteers.<sup><xref ref-type="bibr" rid="bibr47-0960327111417271">47</xref></sup> Elevated levels of total or active ghrelin in cancer cachexia have been reported in cohorts of primarily male lung cancer patients.<sup><xref ref-type="bibr" rid="bibr26-0960327111417271">26</xref></sup> In our study, we report on increased ghrelin levels in a cohort of gastric and colon cancer patients. Specially, high levels of ghrelin were also found among a significant number of cachectic lung cancer patients.<sup><xref ref-type="bibr" rid="bibr26-0960327111417271">26</xref></sup> Our results suggest that the measurement of ghrelin levels may have important clinical implications in treating cancer-related cachexia syndrome. Although leptin levels are associated with weight loss after fasting,<sup><xref ref-type="bibr" rid="bibr48-0960327111417271">48</xref></sup> associations between leptin levels and cancer cachexia are not yet completely elucidated. Thus, lower leptin levels were found in patients with gastrointestinal system cancers, regardless of the degree of weight loss.<sup><xref ref-type="bibr" rid="bibr49-0960327111417271">49</xref></sup> However, association between leptin levels and weight loss was noted in a cohort of lung<sup><xref ref-type="bibr" rid="bibr50-0960327111417271">50</xref></sup> and pancreatic cancer patients.<sup><xref ref-type="bibr" rid="bibr29-0960327111417271">29</xref></sup> We also found a correlation between leptin levels and cancer-induced weight loss, especially in patients with all types of gastrointestinal system cancers. Our results demonstrating a weight-loss-dependent association with cachexia may support the association of leptin with cachexia. Moreover, leptin levels have positive correlation with IL-6 levels and CRP in our study, in all patient groups. This situation may explain that high IL-6 levels related with the cancer progression and invasion. Pyrogenic activity of this proinflammatory cytokine may be responsible for cachexia and weight loss. In addition, IL-6 stimulates the synthesis of APRP. So, adiponectin, ghrelin, and leptin levels have been accelerated by APRP levels. Association between weight loss and levels of proinflammatory cytokines, cytokines, APRP, adiponectin, ghrelin, and leptin levels has not been explained. We found that adiponectin, ghrelin, and leptin highly regulate the energy homeostasis such as cytokines, which affect various central mechanisms.<sup><xref ref-type="bibr" rid="bibr11-0960327111417271">11</xref></sup> Our study revealed an association between cytokine and proinflammatory cell concentrations and APRP in patients with gastrointestinal system cancer. In our study, there is an association between these parameters and in the levels of these hormones, which confirms our hypothesis and is consistent with our previous study.<sup><xref ref-type="bibr" rid="bibr51-0960327111417271">51</xref></sup>
</p>
<p>In conclusion, our results provide evidence for an association between all types of gastrointestinal system cancer-related cachexia and changes in the concentrations of APRPs, cytokines, and hormones. More studies should be performed to confirm this association between cachexia and APRP, cytokines and hormones in patients with gastrointestinal system cancers.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure" id="fn1-0960327111417271">
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0960327111417271">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Loberg</surname>
<given-names>RD</given-names>
</name>
<name>
<surname>Bradley</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Tomlins</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Chinnaiyan</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Pienta</surname>
<given-names>KJ</given-names>
</name>
</person-group>. <article-title>The lethal phenotype of cancer: the molecular basis of death due to malignancy</article-title>. <source>CA Cancer J Clin</source>
<year>2007</year>; <volume>57</volume>: <fpage>225</fpage>–<lpage>241</lpage>.</citation>
</ref>
<ref id="bibr2-0960327111417271">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Polesty</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Dudrick</surname>
<given-names>SJ</given-names>
</name>
</person-group>. <article-title>What we have learned about cachexia in gastrointestinal cancer</article-title>. <source>Dig Dis</source>
<year>2003</year>; <volume>21</volume>: <fpage>198</fpage>–<lpage>213</lpage>.</citation>
</ref>
<ref id="bibr3-0960327111417271">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chamberlain</surname>
<given-names>JS</given-names>
</name>
</person-group>. <article-title>Cachexia in cancer-zeroing in on myosin</article-title>. <source>N Engl J Med</source>
<year>2004</year>; <volume>351</volume>: <fpage>2124</fpage>–<lpage>2125</lpage>.</citation>
</ref>
<ref id="bibr4-0960327111417271">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rubin</surname>
<given-names>H</given-names>
</name>
</person-group>. <article-title>Cancer cachexia: its correlations and causes</article-title>. <source>Proc Natl Acad Sci U S A</source>
<year>2003</year>; <volume>100</volume>: <fpage>5384</fpage>–<lpage>5389</lpage>.</citation>
</ref>
<ref id="bibr5-0960327111417271">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boddeart</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Gerritsen</surname>
<given-names>WR</given-names>
</name>
<name>
<surname>Pinedo</surname>
<given-names>HM</given-names>
</name>
</person-group>. <article-title>On our own way to targeted therapy for cachexia in cancer</article-title>. <source>Curr Opin Oncol</source>
<year>2006</year>; <volume>18</volume>: <fpage>335</fpage>–<lpage>340</lpage>.</citation>
</ref>
<ref id="bibr6-0960327111417271">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saini</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Al-Shants</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Stework</surname>
<given-names>CE</given-names>
</name>
</person-group>. <article-title>Waste management cytokines growth factors and cachexia</article-title>. <source>Cytokine Growth Factor Rev</source>
<year>2006</year>; <volume>17</volume>: <fpage>475</fpage>–<lpage>486</lpage>.</citation>
</ref>
<ref id="bibr7-0960327111417271">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deans</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wigmore</surname>
<given-names>SJ</given-names>
</name>
</person-group>. <article-title>Systemic inflammation, cachexia and prognosis in patients with cancer</article-title>. <source>Curr Opin Clin Nutr Metab Care</source>
<year>2005</year>; <volume>8</volume>: <fpage>265</fpage>–<lpage>269</lpage>.</citation>
</ref>
<ref id="bibr8-0960327111417271">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Acharyya</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ladner</surname>
<given-names>KJ</given-names>
</name>
<name>
<surname>Nelsen</surname>
<given-names>LL</given-names>
</name>
<etal/>
</person-group>. <article-title>Cancer cachexia is regulated by selective targeting of skeletal muscle gene products</article-title>. <source>J Clin Invest</source>
<year>2004</year>; <volume>114</volume>: <fpage>370</fpage>–<lpage>378</lpage>.</citation>
</ref>
<ref id="bibr9-0960327111417271">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ramas</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Marks</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Inui</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Asakawa</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Meguid</surname>
<given-names>MM</given-names>
</name>
</person-group>. <article-title>Cancer anorexia-cachexia syndrome: cytokines and neuropeptides</article-title>. <source>Curr Opin Nutr Metab Care</source>
<year>2004</year>; <volume>7</volume>: <fpage>427</fpage>–<lpage>434</lpage>.</citation>
</ref>
<ref id="bibr10-0960327111417271">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krzystek-Korpacka</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Matusiewich</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Diakowska</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>Impact of weight loss on circulating IL-1, IL-6, IL-8, TNF-α, VEGF-A, VEGF-C and midkine in gastroesophageal cancer patients</article-title>. <source>Clin Biochem</source>
<year>2007</year>; <volume>40</volume>: <fpage>1353</fpage>–<lpage>1360</lpage>.</citation>
</ref>
<ref id="bibr11-0960327111417271">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Have</surname>
<given-names>PJ</given-names>
</name>
</person-group>. <article-title>Peripheral signals conveying metabolic information to the brain: short-term and long-term regulation of food intake and energy homeostasis</article-title>. <source>Exp Biol Med (Maywood)</source>
<year>2001</year>; <volume>226</volume>: <fpage>963</fpage>–<lpage>977</lpage>.</citation>
</ref>
<ref id="bibr12-0960327111417271">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meier</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Gressner</surname>
<given-names>AM</given-names>
</name>
</person-group>. <article-title>Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin and resistin</article-title>. <source>Clin Chem</source>
<year>2004</year>; <volume>50</volume>: <fpage>1511</fpage>–<lpage>1525</lpage>.</citation>
</ref>
<ref id="bibr13-0960327111417271">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Diez</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Iglesias</surname>
<given-names>P</given-names>
</name>
</person-group>. <article-title>The role of the novel adipocyte-derived hormone adiponectin in human disease</article-title>. <source>Eur J Endocrinol</source>
<year>2003</year>; <volume>148</volume>: <fpage>293</fpage>–<lpage>300</lpage>.</citation>
</ref>
<ref id="bibr14-0960327111417271">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arita</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kihara</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Quchi</surname>
<given-names>N</given-names>
</name>
<etal/>
</person-group>. <article-title>Paradoxical decrease of on adipose-specific protein, adiponectin, in obesity</article-title>. <source>Biochem Biophys Res Commun</source>
<year>1999</year>; <volume>257</volume>: <fpage>79</fpage>–<lpage>83</lpage>.</citation>
</ref>
<ref id="bibr15-0960327111417271">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Staiger</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Tschritter</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Machann</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Relationship of serum adiponectin and leptin concentrations with body fat distribution in humans</article-title>. <source>Obes Res</source>
<year>2003</year>; <volume>11</volume>: <fpage>368</fpage>–<lpage>372</lpage>.</citation>
</ref>
<ref id="bibr16-0960327111417271">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pannacciuli</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Vettor</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Milan</surname>
<given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>Anorexia nervosa is characterized by increased adiponectin plasma levels and reduced non-oxidative glucose metabolism</article-title>. <source>J Clin Endocrinol Metab</source>
<year>2003</year>; <volume>88</volume>: <fpage>1748</fpage>–<lpage>1752</lpage>.</citation>
</ref>
<ref id="bibr17-0960327111417271">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>WS</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>WJ</given-names>
</name>
<name>
<surname>Funahashi</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin</article-title>. <source>J Clin Endocrinol Metab</source>
<year>2001</year>; <volume>86</volume>: <fpage>3815</fpage>–<lpage>3819</lpage>.</citation>
</ref>
<ref id="bibr18-0960327111417271">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dal Maso</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Augustin</surname>
<given-names>LJ</given-names>
</name>
<name>
<surname>Karalis</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Circulation adiponectin and endometrial cancer risk</article-title>. <source>J Clin Endocrinol Metab</source>
<year>2004</year>; <volume>89</volume>: <fpage>1160</fpage>–<lpage>1163</lpage>.</citation>
</ref>
<ref id="bibr19-0960327111417271">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miyoshi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Funahashi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kihara</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Association of serum adiponectin levels with breast cancer risk</article-title>. <source>Clin Cancer Res</source>
<year>2003</year>; <volume>9</volume>: <fpage>5699</fpage>–<lpage>5704</lpage>.</citation>
</ref>
<ref id="bibr20-0960327111417271">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ishikawa</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kitayoma</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kazoma</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hiramatsu</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hatano</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Nagawa</surname>
<given-names>H</given-names>
</name>
</person-group>. <article-title>Plasma adiponectin and gastric cancer</article-title>. <source>Clin Cancer Res</source>
<year>2005</year>; <volume>11</volume>: <fpage>466</fpage>–<lpage>472</lpage>.</citation>
</ref>
<ref id="bibr21-0960327111417271">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Jenkins</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Trayhurn</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Expression and secretion of inflammation-related adipokines by human adipocytes differentiated in culture: Integrated response to TNF-α</article-title>. <source>Am J Physiol Endocrinol Metab</source>
<year>2005</year>; <volume>288</volume>: <fpage>E731</fpage>–<lpage>E740</lpage>.</citation>
</ref>
<ref id="bibr22-0960327111417271">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kojima</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hosoda</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Date</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Ghrelin is a growth-hormone-releasing acylated peptide from stomach</article-title>. <source>Nature</source>
<year>1999</year>; <volume>402</volume>: <fpage>656</fpage>–<lpage>660</lpage>.</citation>
</ref>
<ref id="bibr23-0960327111417271">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takoya</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Ariyasu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kanamoto</surname>
<given-names>N</given-names>
</name>
<etal/>
</person-group>. <article-title>Ghrelin strongly stimulates growth hormone release in humans</article-title>. <source>J Clin Endocrinol Metab</source>
<year>2000</year>; <volume>85</volume>: <fpage>4908</fpage>–<lpage>4911</lpage>.</citation>
</ref>
<ref id="bibr24-0960327111417271">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Commentary</surname>
<given-names>Waseem T.</given-names>
</name>
</person-group>: <article-title>Ghrelin’s role in gastrointestinal tract cancer</article-title>. <source>Surg Oncol</source>
<year>2009</year>; <volume>19</volume>(<issue>1</issue>): <comment>e1. PMID:19324542</comment>.</citation>
</ref>
<ref id="bibr25-0960327111417271">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Otto</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Cuntz</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Fruehauf</surname>
<given-names>E</given-names>
</name>
<etal/>
</person-group>. <article-title>Weight gain decreases elevated plasma ghrelin concentrations of patients with an anorexia nervosa</article-title>. <source>Eur J Endocrinol</source>
<year>2001</year>; <volume>145</volume>: <fpage>669</fpage>–<lpage>673</lpage>.</citation>
</ref>
<ref id="bibr26-0960327111417271">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shimizu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Nagaya</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Isobe</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>Increased plasma ghrelin levels in lung cancer cachexia</article-title>. <source>Clin Cancer Res</source>
<year>2003</year>; <volume>9</volume>: <fpage>774</fpage>–<lpage>778</lpage>.</citation>
</ref>
<ref id="bibr27-0960327111417271">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garcia</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Garcia-Toyza</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hijazi</surname>
<given-names>RA</given-names>
</name>
<etal/>
</person-group>. <article-title>Active ghrelin levels and active/total ghrelin ratio in cancer-induced cachexia</article-title>. <source>J Clin Endocrinol Metab</source>
<year>2005</year>; <volume>90</volume>: <fpage>2920</fpage>–<lpage>2926</lpage>.</citation>
</ref>
<ref id="bibr28-0960327111417271">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brichard</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Delporte</surname>
<given-names>MI</given-names>
</name>
<name>
<surname>Lambert</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Adipocytokines in cachexia nervosa: a review focusing on leptin and adiponectin</article-title>. <source>Horm Metab Res</source>
<year>2003</year>; <volume>35</volume>: <fpage>337</fpage>–<lpage>342</lpage>.</citation>
</ref>
<ref id="bibr29-0960327111417271">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brown</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Beikowitz</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Breslow</surname>
<given-names>MJ</given-names>
</name>
</person-group>. <article-title>Weight loss is not associated with hyperleptinemia in humans with pancreatic cancer</article-title>. <source>J Clin Endocrinol Metab</source>
<year>2001</year>; <volume>86</volume>: <fpage>162</fpage>–<lpage>166</lpage>.</citation>
</ref>
<ref id="bibr30-0960327111417271">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bolukbas</surname>
<given-names>FF</given-names>
</name>
<name>
<surname>Kılıc</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Bolukbas</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Serum leptin concentration and advanced gastrointestinal cancers: a case controlled study</article-title>. <source>BMC Cancer</source>
<year>2004</year>; <volume>4</volume>: <fpage>29</fpage>.</citation>
</ref>
<ref id="bibr31-0960327111417271">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lelbach</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Muzes</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Feher</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Current perspectives of catabolic mediators of cancer cachexia</article-title>. <source>Med Sci Monit</source>
<year>2007</year>; <volume>13</volume>: RA <fpage>168</fpage>–<lpage>173</lpage>.</citation>
</ref>
<ref id="bibr32-0960327111417271">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kadomatsu</surname>
<given-names>K</given-names>
</name>
</person-group>, <article-title>Tomomura M, and Muramatsu T. cDNA cloning and sequencing of a new gene intensely expressed in early differentiation stages of embryonal carcinoma cells and mid-gestation period of mouse embryogenesis</article-title>. <source>Biochem Biophys Res Commun</source>
<year>1988</year>; <volume>151</volume>: <fpage>1312</fpage>–<lpage>1318</lpage>.</citation>
</ref>
<ref id="bibr33-0960327111417271">
<label>33</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Fleming</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Henson</surname>
<given-names>DE</given-names>
</name>
</person-group> (eds) <source>American Joint Committee on cancer staging manual</source>. <edition>5th ed</edition>. <publisher-loc>Philadelphia</publisher-loc>: <publisher-name>Lippincott-Raven</publisher-name>, <year>1997</year>.</citation>
</ref>
<ref id="bibr34-0960327111417271">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sanz</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Ovejero</surname>
<given-names>VJ</given-names>
</name>
<name>
<surname>Gonzalez</surname>
<given-names>JJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Mortality risk scales in esophagoctomy for cancer: their usefulness in preoperative patient selection</article-title>. <source>Hepatogastroenterology</source>
<year>2006</year>; <volume>53</volume>: <fpage>869</fpage>–<lpage>873</lpage>.</citation>
</ref>
<ref id="bibr35-0960327111417271">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Onate-Ocana</surname>
<given-names>LF</given-names>
</name>
<name>
<surname>Aiello-Crocifoglio</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Gallardo-Rincón</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>Serum albumin as a significant prognostic factor for patients with gastric carcinoma</article-title>. <source>Ann Surg Oncol</source>
<year>2007</year>; <volume>14</volume>: <fpage>381</fpage>–<lpage>389</lpage>.</citation>
</ref>
<ref id="bibr36-0960327111417271">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gockel</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Dirksen</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Messow</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Iunginger</surname>
<given-names>T.</given-names>
</name>
</person-group> <article-title>Significance of preoperative C-reactive protein as a parameter of the perioperative course and long-term prognosis in squamous cell carcinoma and adenocarcinoma of the esophagus</article-title>. <source>World J Gastroenterol</source>
<year>2006</year>; <volume>12</volume>: <fpage>3746</fpage>–<lpage>3750</lpage>.</citation>
</ref>
<ref id="bibr37-0960327111417271">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nozoe</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Saeki</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Sugimachi</surname>
<given-names>K.</given-names>
</name>
</person-group> <article-title>Significance of preoperative elevation of serum C-reactive protein as an indicator of prognosis in esophageal carcinoma</article-title>. <source>Am J Surg</source>
<year>2001</year>; <volume>182</volume>: <fpage>197</fpage>–<lpage>201</lpage>.</citation>
</ref>
<ref id="bibr38-0960327111417271">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crumley</surname>
<given-names>AB</given-names>
</name>
<name>
<surname>McMillan</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>McKernan</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>An elevated C-reactive protein concentration, prior to surgery, predicts poor cancer-specific survival in patients undergoing resection for gastro-esophageal cancer</article-title>. <source>Br J Cancer</source>
<year>2006</year>; <volume>94</volume>: <fpage>1568</fpage>–<lpage>1571</lpage>.</citation>
</ref>
<ref id="bibr39-0960327111417271">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beecken</surname>
<given-names>WD</given-names>
</name>
<name>
<surname>Kramer</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Jonas</surname>
<given-names>D.</given-names>
</name>
</person-group> <article-title>New molecular mediators in tumor angiogenesis</article-title>. <source>J Cell Mol Med</source>
<year>2000</year>; <volume>4</volume>: <fpage>262</fpage>–<lpage>269</lpage>.</citation>
</ref>
<ref id="bibr40-0960327111417271">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krzystek-Korpacka</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Matusiewicz</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Diakowska</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>Elevation of circulating IL-8 is related to lymph node and distant metastases in esophageal squamous cell carcinomas-implication for clinical evaluation of cancer patient</article-title>. <source>Cytokine</source>
<year>2008</year>; <volume>41</volume>(<issue>3</issue>): <fpage>232</fpage>–<lpage>239</lpage>. <comment>doi: 10.1016/j.cyto. 2007.11.011</comment>.</citation>
</ref>
<ref id="bibr41-0960327111417271">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boedefeld</surname>
<given-names>WM</given-names>
</name>
<name>
<surname>Bland</surname>
<given-names>KI</given-names>
</name>
<name>
<surname>Heslin</surname>
<given-names>MJ.</given-names>
</name>
</person-group> <article-title>Recent insights into angiogenesis, apoptosis, invasion and metastasis in colorectal carcinoma</article-title>. <source>Ann Surg Oncol</source>
<year>2003</year>; <volume>10</volume>: <fpage>839</fpage>–<lpage>851</lpage>.</citation>
</ref>
<ref id="bibr42-0960327111417271">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Macias</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Garcia Perez</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ruiz-Tudela</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> <article-title>Modification of pro-and anti-inflammatory cytokines and vascular-related molecules by tumor necrosis factor-α blockade in patients with rheumatoid arthritis</article-title>. <source>J Rheumatol</source>
<year>2005</year>; <volume>32</volume>: <fpage>2102</fpage>–<lpage>2108</lpage>.</citation>
</ref>
<ref id="bibr43-0960327111417271">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Muramatsu</surname>
<given-names>T.</given-names>
</name>
</person-group> <article-title>Midkine and pleiotrophin: two related proteins involved in development, survival, inflammation and tumorigenesis</article-title>. <source>J Biochem</source>
<year>2002</year>; <volume>132</volume>: <fpage>359</fpage>–<lpage>371</lpage>.</citation>
</ref>
<ref id="bibr44-0960327111417271">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ikematsu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yano</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Aridome</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kikuchi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kumai</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Nagano</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> <article-title>Serum midkine levels are increased in patients with various type of carcinomas</article-title>. <source>Br J Cancer</source>
<year>2000</year>; <volume>83</volume>: <fpage>701</fpage>–<lpage>706</lpage>.</citation>
</ref>
<ref id="bibr45-0960327111417271">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berg</surname>
<given-names>AH</given-names>
</name>
<name>
<surname>Combs</surname>
<given-names>TP</given-names>
</name>
<name>
<surname>Scherer</surname>
<given-names>PE.</given-names>
</name>
</person-group> <article-title>ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism</article-title>. <source>Trends Endocrinol Metab</source>
<year>2002</year>; <volume>13</volume>: <fpage>84</fpage>–<lpage>89</lpage>.</citation>
</ref>
<ref id="bibr46-0960327111417271">
<label>46</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bruun</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Lihn</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Verdich</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Regulation of adiponectin by adipose tissue-derived cytokines: in humans</article-title>. <source>Am J Physiol Endocrinol Metab</source>
<year>2003</year>; <volume>285</volume>: <fpage>E527</fpage>–<lpage>E533</lpage>.</citation>
</ref>
<ref id="bibr47-0960327111417271">
<label>47</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jamieson</surname>
<given-names>NB</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Michael Wallace</surname>
<given-names>A</given-names>
</name>
<name>
<surname>McMillan</surname>
<given-names>DC.</given-names>
</name>
</person-group> <article-title>Adiponectin and the systemic inflammatory response in weight-losing patients with nonsmall cell lung cancer</article-title>. <source>Cytokine</source>
<year>2004</year>; <volume>27</volume>: <fpage>90</fpage>–<lpage>92</lpage>.</citation>
</ref>
<ref id="bibr48-0960327111417271">
<label>48</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wolfe</surname>
<given-names>BE</given-names>
</name>
<name>
<surname>Jimerson</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Orlova</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Mantzoros</surname>
<given-names>CS.</given-names>
</name>
</person-group> <article-title>Effect of dieting on plasma leptin receptor, adiponectin and resistin levels in healthy volunteers</article-title>. <source>Clin Endocrinol (Oxf)</source>
<year>2004</year>; <volume>61</volume>: <fpage>332</fpage>–<lpage>338</lpage>.</citation>
</ref>
<ref id="bibr49-0960327111417271">
<label>49</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dulger</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Alici</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sekeroglu</surname>
<given-names>MR.</given-names>
</name>
<etal/>
</person-group> <article-title>Serum levels of leptin and proinflammatory cytokines in patients with gastrointestinal cancer</article-title>. <source>Int J Clin Pract</source>
<year>2004</year>; <volume>58</volume>: <fpage>545</fpage>–<lpage>549</lpage>.</citation>
</ref>
<ref id="bibr50-0960327111417271">
<label>50</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Simons</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Schols</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Campfield</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Wouters</surname>
<given-names>EF</given-names>
</name>
<name>
<surname>Sanis</surname>
<given-names>WH.</given-names>
</name>
</person-group> <article-title>Plasma concentration of total leptin and human lung-cancer-associated cachexia</article-title>. <source>Clin Sci (Lond)</source>
<year>1997</year>; <volume>93</volume>: <fpage>273</fpage>–<lpage>277</lpage>.</citation>
</ref>
<ref id="bibr51-0960327111417271">
<label>51</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kemık</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Sumer</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kemık</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Hasırcı</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Purisa</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Dulger</surname>
<given-names>AC.</given-names>
</name>
<etal/>
</person-group> <article-title>The relationship among acute-phase response proteins, cytokines and hormones in cachectic patients with colon cancer</article-title>. <source>World J Surg Oncol</source>
<year>2010</year>; <volume>8</volume>: <fpage>85</fpage>.</citation>
</ref>
</ref-list>
</back>
</article>